Developer docs
API playgroundTry for free, no card

Search company profiles

NeuroTrauma Sciences

Full company profile

uuid0009kob

Namestring
NeuroTrauma Sciences
Legal namestring
NeuroTrauma Sciences, LLC
Company typeenum
Private
Founded yearint
2016
Descriptiontext

NeuroTrauma Sciences (NTS) is a privately held, clinical-stage biopharmaceutical company founded in 2016 and headquartered in Alpharetta, Georgia. The company is developing neuroprotective therapeutics for acquired brain injury, with a primary focus on acute ischemic stroke (AIS), and secondary indications in chronic stroke and traumatic brain injury (TBI). NTS targets therapeutic areas where there are no FDA-approved neuroprotective drugs and where more than 100 prior stroke neuroprotection trials have failed, framing its differentiated mechanism as a deliberate response to that clinical attrition. The firm currently has 11-50 employees and is pre-revenue.

NTS's core technology is a neurosteroid prodrug platform licensed exclusively worldwide from Emory University. The lead asset, NTS-104, is a water-soluble prodrug that converts rapidly in plasma to the active metabolite NTS-105, which crosses the blood-brain barrier and engages three receptor targets — full antagonism at the androgen receptor, partial agonism at cellular progesterone receptor B, and full antagonism at the mineralocorticoid receptor. This multi-targeted mechanism produces anti-inflammatory, anti-apoptotic, and anti-edema activity in brain and systemic tissue, with dose-dependent improvements in neurological severity scores, motor function, and infarct size in preclinical eMCAO stroke models. A next-generation candidate designed for subcutaneous or intramuscular administration extends the pipeline beyond intravenous delivery. NTS-104 entered first-in-human dosing in a US Phase 1 study in June 2023 (NCT05547438), with Phase 1 completion planned for 2025 and Phase 2 development in acute ischemic stroke as the next step. The product portfolio is supported by collaborations with Antwerp University Hospital (CENTER-TBI) and research relationships with Emory, University of Miami, Columbia University, and Henry Ford Health.

The company's business model is pre-commercial. NTS is not yet generating revenue and will not do so until regulatory approval and market launch of NTS-104 or pipeline successors, at which point revenue will derive from pharmaceutical product sales to hospitals and healthcare systems via enterprise pharmaceutical distribution channels. Pricing has not been disclosed and will be set post-approval. The company monetizes its current asset base through scientific publication, conference presence (ISC, BIO, NNS), and academic-industry research partnerships rather than product sales. Capital formation to date has been via private funding rounds, with specific amounts, lead investors, and valuation not publicly disclosed. The Emory license carries milestone payments and a single-digit royalty obligation on future sales.

Short descriptiontext

NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neurosteroid prodrug therapeutics, led by NTS-104 for acute ischemic stroke, chronic stroke, and traumatic brain injury. The company was founded in 2016 and is completing Phase 1 trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAlpharetta, United States
HQ citystring
Alpharetta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuroprotective therapeutics, stroke pharmaceuticals, neurosteroid prodrugs, traumatic brain injury drugs, ischemic stroke treatment
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAG
Stroke & Vascular Neurology
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Neuroprotective Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Revenue will be generated through sales of NTS-104 and pipeline compounds upon FDA approval for acute ischemic stroke, chronic stroke, and potentially traumatic brain injury.

neurotraumasciences.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neuroprotective therapeutics for acquired brain injury. Its lead candidate NTS-104 is a water-soluble neurosteroid prodrug administered intravenously that converts in plasma to the active metabolite NTS-105, which crosses the blood-brain barrier and provides anti-inflammatory, anti-apoptotic, and anti-edema activity. The pipeline targets acute ischemic stroke, chronic stroke, and traumatic brain injury.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NTS-104 markedly improved modified neurological severity score (mNSS) in a dose-dependent manner in preclinical eMCAO stroke model
+2 more records
Product overview1 text field

NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing a pipeline of neuroprotective therapeutics for stroke and traumatic brain injury. The core product is NTS-104, a water-soluble intravenous neurosteroid prodrug that converts to the active metabolite NTS-105. The pipeline includes a next-generation candidate for subcutaneous/intramuscular administration. The company was founded in 2016 and completed Phase 1 clinical trials with NTS-104 in 2025.

Product and service2 records
1NTS-104
CategoryLead clinical candidate
Description

Water-soluble neurosteroid prodrug administered intravenously that converts rapidly in plasma to the active metabolite NTS-105. Being developed for acute ischemic stroke and chronic stroke with multi-targeted mechanisms including anti-inflammatory, anti-apoptotic, and anti-edema activity.

2Next-Generation Neurosteroid Candidate
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Antwerp University Hospital, Belgium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-11
Description

NeuroTrauma Sciences entered into a research collaboration with Antwerp University Hospital to support CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI). The collaboration helps fund the continuation of this prospective longitudinal observational study collecting clinical and epidemiological data to identify most effective clinical care and treatment recommendations, validate surrogate biomarkers, and improve classification of TBI. NTS's funding ensures the CENTER-TBI network and infrastructure built over 7+ years will remain intact.

neurotraumasciences.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-12-11
Description

NeuroTrauma Sciences entered into an exclusive worldwide license agreement with Emory University for patents and technology invented at Emory, including NTS-1104 and related compounds. Emory granted NTS exclusive worldwide license for proprietary neuroactive compounds for treatment of acquired brain injury such as ischemic stroke and traumatic brain injury, including concussion. NTS paid an undisclosed license fee and certain expenses to Emory, and Emory will receive milestone payments and a single-digit royalty on future sales.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner identified on NeuroTrauma Sciences Connect page, collaborating on neuroscience research initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner collaborating on neuroscience and drug development research as shown in partnership logos.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner, particularly involving Barclay Morrison III, Ph.D. from Columbia University's Department of Biomedical Engineering who led research on NTS-105 in preclinical TBI models.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner collaborating on neuroscience and brain injury research initiatives.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuroTrauma Sciences

Neuroprotective Biopharmaceuticalsneurotraumasciences.com

NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neurosteroid prodrug therapeutics, led by NTS-104 for acute ischemic stroke, chronic stroke, and traumatic brain injury. The company was founded in 2016 and is completing Phase 1 trials.

What NeuroTrauma Sciences does

NeuroTrauma Sciences (NTS) is a privately held, clinical-stage biopharmaceutical company founded in 2016 and headquartered in Alpharetta, Georgia. The company is developing neuroprotective therapeutics for acquired brain injury, with a primary focus on acute ischemic stroke (AIS), and secondary indications in chronic stroke and traumatic brain injury (TBI). NTS targets therapeutic areas where there are no FDA-approved neuroprotective drugs and where more than 100 prior stroke neuroprotection trials have failed, framing its differentiated mechanism as a deliberate response to that clinical attrition. The firm currently has 11-50 employees and is pre-revenue.

NTS's core technology is a neurosteroid prodrug platform licensed exclusively worldwide from Emory University. The lead asset, NTS-104, is a water-soluble prodrug that converts rapidly in plasma to the active metabolite NTS-105, which crosses the blood-brain barrier and engages three receptor targets — full antagonism at the androgen receptor, partial agonism at cellular progesterone receptor B, and full antagonism at the mineralocorticoid receptor. This multi-targeted mechanism produces anti-inflammatory, anti-apoptotic, and anti-edema activity in brain and systemic tissue, with dose-dependent improvements in neurological severity scores, motor function, and infarct size in preclinical eMCAO stroke models. A next-generation candidate designed for subcutaneous or intramuscular administration extends the pipeline beyond intravenous delivery. NTS-104 entered first-in-human dosing in a US Phase 1 study in June 2023 (NCT05547438), with Phase 1 completion planned for 2025 and Phase 2 development in acute ischemic stroke as the next step. The product portfolio is supported by collaborations with Antwerp University Hospital (CENTER-TBI) and research relationships with Emory, University of Miami, Columbia University, and Henry Ford Health.

The company's business model is pre-commercial. NTS is not yet generating revenue and will not do so until regulatory approval and market launch of NTS-104 or pipeline successors, at which point revenue will derive from pharmaceutical product sales to hospitals and healthcare systems via enterprise pharmaceutical distribution channels. Pricing has not been disclosed and will be set post-approval. The company monetizes its current asset base through scientific publication, conference presence (ISC, BIO, NNS), and academic-industry research partnerships rather than product sales. Capital formation to date has been via private funding rounds, with specific amounts, lead investors, and valuation not publicly disclosed. The Emory license carries milestone payments and a single-digit royalty obligation on future sales.

NeuroTrauma Sciences firmographics

Firmographics
Name
NeuroTrauma Sciences
Legal name
NeuroTrauma Sciences, LLC
Website
https://neurotraumasciences.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neurosteroid prodrug therapeutics, led by NTS-104 for acute ischemic stroke, chronic stroke, and traumatic brain injury. The company was founded in 2016 and is completing Phase 1 trials.
Ownership category
akta.pro rank

NeuroTrauma Sciences industry classification

Industry
Product category
Neuroprotective Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAIAG
Stroke & Vascular Neurology
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Neuroprotective therapeutics
  • Stroke pharmaceuticals
  • Neurosteroid prodrugs
  • Traumatic brain injury drugs
  • Ischemic stroke treatment

Where NeuroTrauma Sciences is headquartered

Location

Headquarters

HQ city
Alpharetta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuroTrauma Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company. Revenue will be generated through sales of NTS-104 and pipeline compounds upon FDA approval for acute ischemic stroke, chronic stroke, and potentially traumatic brain injury.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

NeuroTrauma Sciences product offering

Product offering

Core offering

NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neuroprotective therapeutics for acquired brain injury. Its lead candidate NTS-104 is a water-soluble neurosteroid prodrug administered intravenously that converts in plasma to the active metabolite NTS-105, which crosses the blood-brain barrier and provides anti-inflammatory, anti-apoptotic, and anti-edema activity. The pipeline targets acute ischemic stroke, chronic stroke, and traumatic brain injury.

Product overview

NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing a pipeline of neuroprotective therapeutics for stroke and traumatic brain injury. The core product is NTS-104, a water-soluble intravenous neurosteroid prodrug that converts to the active metabolite NTS-105. The pipeline includes a next-generation candidate for subcutaneous/intramuscular administration. The company was founded in 2016 and completed Phase 1 clinical trials with NTS-104 in 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • NTS-104 Water-soluble neurosteroid prodrug administered intravenously that converts rapidly in plasma to the active metabolite NTS-105. Being developed for acute ischemic stroke and chronic stroke with multi-targeted mechanisms including anti-inflammatory, anti-apoptotic, and anti-edema activity.
  • Next-Generation Neurosteroid Candidate

Quantifiable outcome

  • NTS-104 markedly improved modified neurological severity score (mNSS) in a dose-dependent manner in preclinical eMCAO stroke model
  • +2 more outcomes

Companies that use NeuroTrauma Sciences

Customer profile

Segments3 records

Ideal customer profiles2 records

NeuroTrauma Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

NeuroTrauma Sciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Antwerp University Hospital, BelgiumcoreStrategic or Co-development Partner · 11 May 2021NeuroTrauma Sciences entered into a research collaboration with Antwerp University Hospital to support CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI). The collaboration helps fund the continuation of this prospective longitudinal observational study collecting clinical and epidemiological data to identify most effective clinical care and treatment recommendations, validate surrogate biomarkers, and improve classification of TBI. NTS's funding ensures the CENTER-TBI network and infrastructure built over 7+ years will remain intact.
  • Emory UniversitycoreOEM/ Whitelabel/ Licensing Partner · 11 December 2019NeuroTrauma Sciences entered into an exclusive worldwide license agreement with Emory University for patents and technology invented at Emory, including NTS-1104 and related compounds. Emory granted NTS exclusive worldwide license for proprietary neuroactive compounds for treatment of acquired brain injury such as ischemic stroke and traumatic brain injury, including concussion. NTS paid an undisclosed license fee and certain expenses to Emory, and Emory will receive milestone payments and a single-digit royalty on future sales.
  • University of MiamiminorStrategic or Co-development PartnerResearch partner identified on NeuroTrauma Sciences Connect page, collaborating on neuroscience research initiatives.
  • Emory UniversitycoreStrategic or Co-development PartnerResearch partner collaborating on neuroscience and drug development research as shown in partnership logos.
  • Columbia UniversityminorStrategic or Co-development PartnerResearch partner, particularly involving Barclay Morrison III, Ph.D. from Columbia University's Department of Biomedical Engineering who led research on NTS-105 in preclinical TBI models.
  • Henry Ford HealthminorStrategic or Co-development PartnerResearch partner collaborating on neuroscience and brain injury research initiatives.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

NeuroTrauma Sciences competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

NeuroTrauma Sciences social profiles

Digital presence

NeuroTrauma Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuroTrauma Sciences leadership team

Management profile

Number of profiles

Profiles7 records

NeuroTrauma Sciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuroTrauma Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroTrauma Sciences

What does NeuroTrauma Sciences do?

NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neuroprotective therapeutics for acquired brain injury. Its lead candidate NTS-104 is a water-soluble neurosteroid prodrug administered intravenously that converts in plasma to the active metabolite NTS-105, which crosses the blood-brain barrier and provides anti-inflammatory, anti-apoptotic, and anti-edema activity. The pipeline targets acute ischemic stroke, chronic stroke, and traumatic brain injury.

Is NeuroTrauma Sciences a public or private company?

NeuroTrauma Sciences is a private company. It is classified as unknown and is currently operating.

When was NeuroTrauma Sciences founded?

NeuroTrauma Sciences was founded in 2016. It employs 11 to 50 people.

Where is NeuroTrauma Sciences based?

NeuroTrauma Sciences is headquartered in Alpharetta, United States, in the North America region.

How does NeuroTrauma Sciences make money?

One revenue line is on record: pharmaceutical Product Sales.

Does NeuroTrauma Sciences have an API?

No public API is recorded for NeuroTrauma Sciences.

What industry is NeuroTrauma Sciences in?

NeuroTrauma Sciences's product category is Neuroprotective Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAKAIAG, Stroke & Vascular Neurology. Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNeuroTrauma Sciences Appoints Kevin Pong, PhD, MBA as Chief Business OfficerNeuroTrauma Sciences, a private biopharmaceutical company developing neuroprotective therapeutics for central nervous system injuries, announced the appointment of Kevin Pong, PhD, MBA as Chief Business Officer. Dr. Pong brings over 20 years of industry experience in business development and licensing, having previously served as CBO at Anima Biotech and in leadership roles at Summit Therapeutics, Sunovion Pharmaceuticals, Endo Pharmaceuticals, and Wyeth. In this role, he will lead the company's global business development, licensing, and alliance management activities as NTS advances its lead program NTS-104 in stroke through clinical development.PR NewswireNeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104NeuroTrauma Sciences has commenced first-in-human dosing of its investigational drug NTS-104 in a Phase 1 safety study involving 32 healthy US participants across four cohorts. The single-dose, randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of the intravenous neuroprotective compound being developed for stroke and other CNS injuries. The company plans to conduct a Phase 2 study of NTS-104 in acute ischemic stroke following completion of this trial.PR NewswireNeuroTrauma Sciences Announces Key Appointments to its Executive Leadership TeamNeuroTrauma Sciences appointed Marc de Somer as Chief Medical Officer and Martin Rabe as Executive Vice President of Regulatory Affairs and Quality Assurance. The company aims to leverage their expertise in clinical development and regulatory affairs as it prepares to initiate dosing in a Phase 1 trial for its lead program, NTS-104, targeting stroke.PR NewswireNeuroTrauma Sciences Neuroactive Compound NTS-105 Decreases Cell Death in Preclinical Model of Traumatic Brain InjuryNeuroTrauma Sciences presented preclinical data on its neuroactive compound NTS-105 at the 39th Annual Symposium of the National Neurotrauma Society in Atlanta, demonstrating that the molecule reduced cell death across a wide concentration range in in vitro models of traumatic brain injury. The study, conducted by researchers at Columbia University, found that NTS-105 at concentrations between 0.1nM and 30nM was significantly neuroprotective compared to progesterone, which has shown limited clinical efficacy. The company indicated it plans to advance NTS-105 into clinical trials for treating traumatic brain injury and stroke.PR NewswireNeuroTrauma Sciences Presents Update on Neuroprotective Compounds NTS-104 and NTS-105 at the 12th Annual Traumatic Brain Injury ConferenceNeuroTrauma Sciences, a private biopharmaceutical company, presented preclinical results for its lead drug candidates NTS-104 and NTS-105 at the 12th Annual Traumatic Brain Injury Conference in Washington, DC on June 7, 2022. The novel neurosteroid compounds demonstrated improved functional outcomes and reduced acute inflammatory markers in rat models of traumatic brain injury and ischemic stroke. The company expects NTS-104 to enter Phase 1 clinical trials in Q4 2022, with issued composition-of-matter and method-of-use patents in place.PR NewswireNeuroTrauma Sciences Enters Collaboration to Support "CENTER-TBI" Research in Traumatic Brain InjuryNeuroTrauma Sciences (NTS) has entered a research collaboration with Antwerp University Hospital, Belgium, to support the CENTER-TBI study, a large European observational research project on traumatic brain injury. The partnership will enable continued meta-analyses of data from over 5,700 patients across Europe, Israel, India, and Australia, while NTS will leverage these insights to inform clinical trial planning for its therapeutic candidates. NTS plans to advance its lead compound NTS-104 into clinical trials for mild TBI in 2022.PR NewswireNeuroTrauma Sciences Announces Expansion of Its Executive Leadership TeamNeuroTrauma Sciences (NTS), a private biopharmaceutical company focused on acquired brain injury therapies, announced the appointment of three senior executives: Judith Hedstrom as Chief Operating Officer, Anthony Caggiano as Chief Medical Officer and Head of Research & Development, and David Lawrence as Chief Financial Officer. The three appointees bring combined decades of experience from companies including Acorda Therapeutics and other clinical-stage biopharmaceutical firms. CEO Carl Long stated the hires are timely as NTS prepares to advance its lead program NTS-104 to an IND submission later in 2021.PR NewswireNeuroTrauma Sciences Appoints Dr. Todd Verdoorn as Vice President of Research and DevelopmentNeuroTrauma Sciences announced the appointment of Dr. Todd Verdoorn as Vice President of Research and Development, effective immediately. Dr. Verdoorn brings over 20 years of experience in neurological disease drug development, having previously served as Chief Scientific Officer at DiaMedica and working with Bristol-Myers Squibb's stroke group. The company stated that his expertise will provide guidance as NeuroTrauma Sciences progresses toward clinical trials for its drug candidates targeting stroke and traumatic brain injury.PR NewswireNeuroTrauma Sciences Enters Into Worldwide License Agreement with Emory University for Molecules to Treat Stroke and Traumatic Brain InjuryNeuroTrauma Sciences has entered into an exclusive worldwide license agreement with Emory University for patents and technology related to NTS-1104, a neuroactive small molecule compound for treating ischemic stroke and traumatic brain injury. Under the agreement, NTS will pay an undisclosed license fee and expenses to Emory, while Emory will receive milestone payments and a single-digit royalty on future sales. NTS plans to immediately undertake Investigational New Drug (IND)-enabling studies with the goal of initiating a Phase 1 clinical trial in stroke as soon as possible.PR NewswireNeuroTrauma Sciences and Henry Ford Health System Announce Research and License Agreements to Develop Exosome Technology for Neurological InjuryNeuroTrauma Sciences and Henry Ford Health System have established a new subsidiary, NeurExo Sciences, LLC, to advance exosome technology for treating neurological injuries such as stroke and traumatic brain injury. Under the agreement, NeurExo will license intellectual property from Henry Ford and fund research led by Dr. Michael Chopp, gaining worldwide commercial rights to resulting product candidates.